Hypofractionated stereotactic boost in intermediate risk prostate carcinoma

Dose escalation may improve curability in intermediate-risk prostate carcinoma. A multi-centre national program was developed to assess toxicity and tumour response with hypofractionated stereotactic boost after conventional radiotherapy in intermediate-risk prostate cancer.
UroToday

Leave a Reply

  • (will not be published)

XHTML: You can use these tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>